| Indication and Important Safety Information |
| Indication |
XENLETA is a pleuromutilin antibacterial indicated for the treatment of adults with
community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
|
|
Usage
|
|
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XENLETA and other antibacterial drugs, XENLETA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
|
|
Important Safety Information
|
|
CONTRAINDICATIONS
|
|
XENLETA is contraindicated in patients with known hypersensitivity to XENLETA or pleuromutilins.
|
|
XENLETA tablets are contraindicated for use with CYP3A4 substrates that prolong the QT interval.
|
|
WARNINGS AND PRECAUTIONS
|
|
XENLETA has the potential to prolong the QT interval. Avoid XENLETA in patients with known QT prolongation, ventricular arrhythmias, and patients receiving drugs that may prolong the QT interval.
|
|
Based on animal studies, XENLETA may cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception.
|
|
Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including XENLETA, with severity ranging from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.
|
|
ADVERSE REACTIONS
|
The most common adverse reactions (≥2%) for (a) XENLETA Injection are administration site reactions, hepatic enzyme elevation, nausea, hypokalemia, insomnia, and headache and
(b) XENLETA Tablets are diarrhea, nausea, vomiting, and hepatic enzyme elevation.
|
|
USE IN SPECIFIC POPULATIONS
|
|
In patients with severe hepatic impairment, reduce the dosage of XENLETA Injection to 150 mg infused over 60 minutes every 24 hours. XENLETA Tablets are not recommended in patients with moderate or severe hepatic impairment due to insufficient information to provide dosing recommendations.
|
|
Avoid XENLETA Injection and Tablets with concomitant strong or moderate CYP3A or P-gp inducers. Monitor for reduced efficacy of XENLETA.
|
|
Avoid XENLETA Tablets with strong CYP3A or P-gp inhibitors.
|
|
Monitor for adverse reactions of sensitive CYP3A substrates administered with XENLETA Tablets.
|
|
XENLETA has not been studied in pregnant women. Verify pregnancy status in females prior to initiating XENLETA and advise females to use contraception during treatment and for 2 days after the final dose. Lactating women should pump and discard milk for the duration of treatment with XENLETA and for 2 days after the final dose.
|
|
To report SUSPECTED ADVERSE REACTIONS, or administration during pregnancy, contact Nabriva Therapeutics US, Inc. at 1-855-5NABRIVA or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
|
|
Please see Full Prescribing Information for XENLETA.
|
|
References:
|
|
|
|
Privacy Notice
|
Disclaimer
|
Unsubscribe
|
|
All trademarks are the property of Nabriva Therapeutics Ireland DAC
Distributed by Nabriva Therapeutics US, Inc.
© 2020 Nabriva Therapeutics US, Inc.
PM-US-LEF-0290 NOV 2020
|
|
